Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 4
2003 5
2004 4
2005 4
2006 2
2007 3
2008 4
2009 11
2010 5
2011 9
2012 9
2013 9
2014 13
2015 19
2016 12
2017 10
2018 4
2019 7
2020 7
2021 6
2022 5
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15277417

140 results

Results by year

Filters applied: . Clear all
Page 1
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Madsbad S, et al. Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335. Diabetes Care. 2004. PMID: 15161785 Clinical Trial.
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. Degn KB, et al. Diabetes. 2004 May;53(5):1187-94. doi: 10.2337/diabetes.53.5.1187. Diabetes. 2004. PMID: 15111485 Clinical Trial.
140 results